From 1993 to early 2000, multiple clinical trials demonstrated that renin–angiotensin system blockade slows the renal decline in DKD by 5–7 mL/min/year, establishing its central role in DKD treatment [9,10,11]. The gene discussed is REN; the disease is diabetic kidney disease.